The Claim
In obese mice, administration of bimagrumab in combination with incretin-based therapeutics increases caloric expenditure, and omics analyses indicate that this increase is mediated by activation of thermogenic pathways in adipose tissue.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese mice, a combination of bimagrumab and incretin-based drugs increases the amount of energy the body burns, and molecular analyses show this is due to activation of heat-producing pathways in fat tissue.
See the scientific wording
In obese mice, bimagrumab increases caloric expenditure when combined with incretin-based therapeutics, and omics analyses suggest this is mediated through activation of thermogenic pathways in adipose tissue.
Blocking a specific receptor in fat tissue turns on heat-producing processes that burn more calories, especially when another treatment is also present. This causes the body to lose more fat without losing muscle.
What the research says
1 studyStudy: 2180-LB: Bimagrumab Augments Metabolic Rate to Improve Incretin-Induced Weight Loss in Obese Mice
In obese mice, a drug called bimagrumab helps burn more calories when used with weight-loss drugs, and scientists found it turns on fat-burning heat-producing pathways in fat tissue — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.